Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Stopped early · Phase 1

Conditions studied: Lymphoma, Non-Hodgkin's

In brief

The purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects with previously untreated follicular NHL.

Key facts

Study ID

NCT00651443

Run by

Biogen

People needed

20

Starts

2008-08-01

Expected to finish

2010-12-01

Last updated by the study team

2011-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent (signed and dated).
• Age equal or greater than 18 at the time of consent.
• Histologically confirmed follicular NHL according to the Revised European American Lymphoma (REAL)/ World Health Organization (WHO) classification (from initial diagnosis) Grades 1,2, or 3a.
• At least 2 malignant lymph nodes of similar size (>1 cm in minimal dimension) and location that are readily accessible for excisional biopsy at the time of study entry.
• Consent to 1 pretreatment and 1 post-treatment excisional biopsy of accessible tumor.
• Acceptable hematologic, hepatic, and renal function parameters.
• WHO Performance Status equal or less than 2.
• Subjects of reproductive potential must agree to follow accepted birth control methods.

You may not qualify if…

• Presence of lymphoma in CNS.
• Previous systemic anticancer treatment for NHL (including but not limited to radiation, myeloablative, or investigational therapy).
• Concurrent treatment with systemic steroids within 14 days of Day 1.
• Evidence of transformed lymphoma.
• Presence of malignancies within 3 years of Study Day 1 (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, or basal or squamous cell skin cancer).
• History of HIV infection or AIDS.
• Serious nonmalignant disease.
• Pregnant.
• Inability to comply with study and follow-up procedures.
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.

Where it is running

• Research Site — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.